SG11201509367RA - Methods for predicting and improving the survival of colorectal cancer patients - Google Patents
Methods for predicting and improving the survival of colorectal cancer patientsInfo
- Publication number
- SG11201509367RA SG11201509367RA SG11201509367RA SG11201509367RA SG11201509367RA SG 11201509367R A SG11201509367R A SG 11201509367RA SG 11201509367R A SG11201509367R A SG 11201509367RA SG 11201509367R A SG11201509367R A SG 11201509367RA SG 11201509367R A SG11201509367R A SG 11201509367RA
- Authority
- SG
- Singapore
- Prior art keywords
- predicting
- survival
- improving
- methods
- colorectal cancer
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 title 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 title 1
- 230000004083 survival effect Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
- G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
- G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/54—Determining the risk of relapse
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361825998P | 2013-05-21 | 2013-05-21 | |
| PCT/IB2014/061606 WO2014188363A1 (en) | 2013-05-21 | 2014-05-21 | Methods for predicting and improving the survival of colorectal cancer patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509367RA true SG11201509367RA (en) | 2015-12-30 |
Family
ID=50896377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509367RA SG11201509367RA (en) | 2013-05-21 | 2014-05-21 | Methods for predicting and improving the survival of colorectal cancer patients |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9903867B2 (en) |
| EP (2) | EP2999966B1 (en) |
| JP (1) | JP6478417B2 (en) |
| KR (1) | KR20160009070A (en) |
| AU (1) | AU2014269946A1 (en) |
| CA (1) | CA2912989A1 (en) |
| HK (1) | HK1223156A1 (en) |
| MX (1) | MX2015016065A (en) |
| SG (1) | SG11201509367RA (en) |
| WO (1) | WO2014188363A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102332655B1 (en) * | 2020-05-18 | 2021-11-30 | 고려대학교 산학협력단 | Biomarker for prognosing colorectal cancer, and use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5532138A (en) | 1990-04-26 | 1996-07-02 | Behringwerke Ag | Method and kits for determining peroxidatively active catalysts |
| US5332662A (en) | 1992-07-31 | 1994-07-26 | Syntex (U.S.A.) Inc. | Methods for determining peroxidatively active substances |
| EP0716746B1 (en) | 1993-09-03 | 1999-03-17 | Behringwerke Ag | Fluorescent oxygen channeling immunoassays |
| US20040229294A1 (en) * | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB surface receptor complexes as biomarkers |
| CA2521077A1 (en) * | 2003-04-01 | 2004-10-28 | Monogram Biosciences, Inc. | Erbb surface receptor complexes as biomarkers |
| MX2009003048A (en) | 2006-09-21 | 2009-09-07 | Prometheus Lab Inc | Antibody-based arrays for detecting multiple signal transducers in rare circulating cells. |
| CA2693013A1 (en) | 2007-07-13 | 2009-01-22 | Prometheus Laboratories Inc. | Drug selection for lung cancer therapy using antibody-based arrays |
| CN102016581B (en) | 2008-02-25 | 2014-07-30 | 雀巢产品技术援助有限公司 | Drug selection for breast cancer therapy using antibody-based arrays |
| US8396228B2 (en) | 2008-02-27 | 2013-03-12 | Stethoscope Technologies, Inc. | Floating ballast mass active stethoscope or sound pickup device |
| US8137919B2 (en) * | 2008-04-10 | 2012-03-20 | Montefiore Medical Center | Method of determining the sensitivity of cancer cells to EGFR inhibitors including cetuximab, panitumumab and erlotinib |
| AU2010248884B2 (en) | 2009-05-14 | 2015-04-02 | Nestec S.A. | Biomarkers for determining sensitivity of breast cancer cells to HER2-targeted therapy |
| JP5795311B2 (en) | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | Drug selection for gastric cancer therapy using antibody-based arrays |
| WO2011050069A1 (en) | 2009-10-20 | 2011-04-28 | Prometheus Laboratories Inc. | Proximity-mediated assays for detecting oncogenic fusion proteins |
| US20120231965A1 (en) * | 2011-02-03 | 2012-09-13 | Prometheus Laboratories Inc. | Drug selection for colorectal cancer therapy using antibody-based arrays |
| EP2908132B8 (en) * | 2011-03-02 | 2019-06-12 | Nestec S.A. | Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures |
-
2014
- 2014-05-21 CA CA2912989A patent/CA2912989A1/en not_active Abandoned
- 2014-05-21 EP EP14728658.7A patent/EP2999966B1/en not_active Not-in-force
- 2014-05-21 JP JP2016514519A patent/JP6478417B2/en not_active Expired - Fee Related
- 2014-05-21 KR KR1020157035993A patent/KR20160009070A/en not_active Application Discontinuation
- 2014-05-21 WO PCT/IB2014/061606 patent/WO2014188363A1/en active Application Filing
- 2014-05-21 EP EP18168596.7A patent/EP3373010A1/en not_active Withdrawn
- 2014-05-21 MX MX2015016065A patent/MX2015016065A/en unknown
- 2014-05-21 SG SG11201509367RA patent/SG11201509367RA/en unknown
- 2014-05-21 AU AU2014269946A patent/AU2014269946A1/en not_active Abandoned
-
2015
- 2015-12-30 US US14/985,190 patent/US9903867B2/en not_active Expired - Fee Related
-
2016
- 2016-09-30 HK HK16111426.3A patent/HK1223156A1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP6478417B2 (en) | 2019-03-06 |
| EP2999966A1 (en) | 2016-03-30 |
| EP2999966B1 (en) | 2018-04-25 |
| AU2014269946A1 (en) | 2015-12-03 |
| US9903867B2 (en) | 2018-02-27 |
| KR20160009070A (en) | 2016-01-25 |
| EP3373010A1 (en) | 2018-09-12 |
| HK1223156A1 (en) | 2017-07-21 |
| JP2016520198A (en) | 2016-07-11 |
| MX2015016065A (en) | 2016-03-21 |
| CA2912989A1 (en) | 2014-11-27 |
| WO2014188363A1 (en) | 2014-11-27 |
| US20160169898A1 (en) | 2016-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1216991A1 (en) | Cancer vaccines and methods of treatment using the same | |
| IL273090B (en) | Methods and compositions for the treatment of cancer | |
| HK1220110A1 (en) | Methods of treating lung cancer | |
| SG11201508223YA (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| ZA201507733B (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| HK1219489A1 (en) | Methods of treating colorectal cancer | |
| HK1213817A1 (en) | Methods of treating cancer | |
| ZA201604370B (en) | Prostate cancer gene profiles and methods of using the same | |
| HK1225967A1 (en) | Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers | |
| HK1219513A1 (en) | Methods of treating cancer | |
| IL244632A0 (en) | Cancer biomarker and diagnostic | |
| HK1223547A1 (en) | Methods for the treatment of cancer | |
| LT2984108T (en) | Anti-s100a7 antibodies for the treatment and diagnosis of cancer | |
| HK1215390A1 (en) | Model of colorectal cancer | |
| HK1213475A1 (en) | Combination of ro5503781, capecitabine and oxaliplantin for cancer therapy ro5503781 | |
| HK1223156A1 (en) | Methods for predicting and improving the survival of colorectal cancer patients | |
| EP3050975A4 (en) | Method for predicting the response to chemotherapy treatment in patients suffering from colorectal cancer | |
| EP3003371A4 (en) | Materials and methods for treatment of liver cancer background of the invention | |
| GB2519829B (en) | Methods for monitoring treatment response and relapse in breast cancer | |
| PL3016948T3 (en) | 2-acylaminothiazoles for the treatment of cancer | |
| HK1214502A1 (en) | Combination of ro5503781 and capecitabine for cancer therapy ro5503781 | |
| GB201302884D0 (en) | Novel methods for diagnosis and therapy |